Abstracts Archive - Page 654 of 2607 - ACR Meeting Abstracts

Abstract Number: 1561 • ACR Convergence 2022
Development of Posterior Uveitis in Behçet’s Syndrome Patients with Vitreous Cells Without Any Other Posterior Involvement
Didar Ucar¹, Basak Ecem Bircan², Nigar Rustamli³, Bilge Batu Oto¹, Vedat Hamuryudan⁴, Sinem Nihal Esatoglu⁵ and gulen Hatemi⁵, ¹Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Ophthalmology, Istanbul, Turkey, ²Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Istanbul, Turkey, ⁴Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ⁵Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: A considerable number of patients with Behçet's syndrome (BS) have vitreous cells on slit lamp examination at the time of diagnosis. However, the prognostic…
Abstract Number: 1563 • ACR Convergence 2022
Common Femoral Vein Wall Thickness Measurement as a Diagnostic Test in Incomplete Behçet’s Disease
Fatma Alibaz-Oner¹, seda kutluğ ağaçkıran², Rabia Ergelen³, Fatma Temiz³, efe Soydemir³, Tulin Ergun⁴ and Haner Direskeneli⁵, ¹Marmara University, Rheumatology, Istanbul, Turkey, ²Marmara University School of Medicine, Division of Rheumatology, Istanbul, Turkey, ³Marmara University, School of Medicine, Departmant of Internal Medicine, Istanbul, Turkey, ⁴Marmara University, School of Medicine, Department of Dermatology, Istanbul, Turkey, ⁵Marmara University, Rheumatology, Istanbul, Istanbul, Turkey
Background/Purpose: Diagnosing Behçet's Disease (BD) can be a clinical challenge in patients presenting with limited organ manifestations, especially with single major organ involvement. We reported…
Abstract Number: 1560 • ACR Convergence 2022
Modulation of NKG2D Expression on NK, NKT and CD8+ T Lymphocytes by in Vitro Treatments of Immune Cells from Patients with Behçet Disease
Martina Bonacini¹, Francesco Muratore¹, Giovanna Restuccia², Laura Albertazzi², Piera Zaldini², Luca Cimino³, Rossana Colla², Alessandro Zerbini¹, Carlo Salvarani⁴ and Stefania Croci¹, ¹Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Reggio Emilia, Italy, ²Azienda Unità Sanitaria Locale – IRCCS di Reggio Emilia, Reggio Emilia, Italy, ³Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, University of Modena and Reggio Emilia, Reggio Emilia, Italy, ⁴Azienda Unità Sanitaria Locale-IRCCS di Reggio Emilia, Università di Modena e Reggio Emilia, Reggio Emilia, Italy
Background/Purpose: Behçet disease (BD) is an inflammatory chronic disease characterized by alternation of active and inactive phases. Steroids, Colchine, Azathioprine (Aza) and interferon α are…
Abstract Number: 1541 • ACR Convergence 2022
MRI Digital Artery Volume Index (DAVIX) Predicts Future Digital Ulcers and Disease Progression in Systemic Sclerosis
Michael Hughes¹, Stefano Di Donato², Klodian Gjeloshi³, Giuseppina Abignano⁴, Fiammetta Danzo³, Giovanni Lettieri G⁴, Enrico De Lorenzis², Dominic Bertham⁵, Philip O’Connor², Olga Kubassova⁶ and Francesco Del Galdo², ¹Department of Rheumatology, Tameside and Glossop Integrated Care NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health and NIHR Biomedical Research Centre, University of Leeds, Leeds, United Kingdom, ³University of Campania ‘‘Luigi Vanvitelli’’, Napoli, Italy, ⁴Istituto Reumatologico Lucano (IReL), Azienda Ospedaliera Regionale San Carlo, Potenza, Italy, ⁵NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Image Analysis Group, London, United Kingdom
Background/Purpose: Fibroproliferative vasculopathy in systemic sclerosis (SSc) is caused by neointima proliferation is a key pathologic feature of SSc which results in arterial vessel narrowing…
Abstract Number: 1567 • ACR Convergence 2022
Refractory Macular Edema Due to Behçet’s Disease. Multicenter Comparative Study of Adalimumab and Certolizumab Pegol
José Luis Martín-Varillas¹, Lara Sánchez-Bilbao², Vanesa Calvo Río³, Alf Adán⁴, Inés Hernanz Rodríguez⁴, Miguel Cordero Coma⁵, David Díaz Valle⁶, Patricia Fanlo⁷, Juan Ramón de Dios⁸, A. Garcia-Aparicio⁹, Sergio Rodriguez Montero¹⁰, Vega Jovani Casano¹¹, Patricia Moya Alvarado¹², eva Peña Sainz-Pardo¹³, José Luis Hernández² and Ricardo Blanco¹⁴, ¹Hospital de Laredo, Laredo, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Spain, ³Valdecilla Hospital, Santander, Spain, ⁴H. Clinic, Barcelona, Spain, ⁵Hospital de León, León, Spain, ⁶Hospital Clínico San Carlos, Madrid, Spain, ⁷Complejo Hospitalario de Navarra, Navarra, Spain, ⁸Hospital de Araba, Araba, Spain, ⁹Hospital Universitario de Toledo, Toledo, Spain, ¹⁰Virgen de Valme University Hospital, Sevilla, Spain, ¹¹National Health system, Alicante, Spain, ¹²Hospital Parc Tauli, Barcelona, Spain, ¹³Hospital Universitario 12 de Octubre, Madrid, Spain, ¹⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Cystoid Macular Edema (CME) is the leading cause of blindness in non-infectious uveitis. Behçet's disease (BD) is one of the diseases most frequently associated…
Abstract Number: 1571 • ACR Convergence 2022
Coronary Arteritis and Periarteritis Secondary to IgG4-related Disease in a Large, Single-center Cohort
Guy Katz¹, sandeep hedgire¹, James Stone², Sebastian Perez-Espina¹, Ana Fernandes¹, Cory Perugino¹, Zachary Wallace¹ and John Stone³, ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Reading, MA, ³Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic autoimmune fibroinflammatory disease capable of affecting most organ systems. Large-vessel vasculitis is a well-described manifestation of the disease.…
Abstract Number: 1569 • ACR Convergence 2022
Lung Involvement in VEXAS Syndrome
Marta Casal Moura¹, Misbah Baqir¹, Yasmeen Tandon², Matthew J. Samec³, Kaaren K. Reichard⁴, Abhishek Mangaonkar⁵, Ronald S. Go⁵, Kenneth J. Warrington⁶, Mrinal Patnaik⁷, Matthew J. Koster⁶ and Jay H. Ryu¹, ¹Mayo Clinic, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Rochester, USA, Rochester, ²Mayo Clinic, Radiology, Rochester, USA, Rochester, ³Mayo Clinic, Division of Rheumatology, Department of Medicine, Rochester, USA, Rochester, ⁴Mayo Clinic, Department of Laboratory Medicine and Pathology, Rochester, USA, Rochester, ⁵Mayo Clinic, Division of Hematology, Department of Medicine, Rochester, USA, Rochester, ⁶Mayo Clinic, ROCHESTER, MN, ⁷Mayo Clinic, Division of Hematology, Department of Medicine, Rochester, United States of America, Rochester
Background/Purpose: Vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome is a recently identified disorder caused by somatic mutations in the UBA1 gene of myeloid cells.…
Abstract Number: 1572 • ACR Convergence 2022
CD40, BLK and BANK1 in the Pathogenesis of Immunoglobulin-A Vasculitis
Fernanda Genre¹, Sara Remuzgo-Martinez¹, Veronica Pulito-Cueto¹, JOAO CARLOS BATISTA LIZ², Diana Prieto-Peña¹, Belén Atienza-Mateo¹, Belén Sevilla-Pérez³, Javier Llorca⁴, Norberto Ortego⁵, María Teresa Leonardo⁶, Ana Peñalba⁶, F. Javier Narváez⁷, Luis Martín-Penagos⁸, Emilio Rodrigo⁸, Cristina Gomez-Fernandez⁹, Lara Belmar-Vega⁸, José A. Miranda-Filloy¹⁰, Luis Caminal-Montero¹¹, Paz Collado¹², Pedro Rodriguez-Jimenez¹³, Diego De Argila¹⁴, Patricia Quiroga-Colina¹⁵, Esther Vicente-Rabaneda¹⁶, Enrique Rubio¹⁷, Manuel León Luque¹⁷, Juan María Blanco-Madrigal¹⁸, Eva Galíndez-Agirregoikoa¹⁹, Javier Martín²⁰, Santos Castañeda¹⁶, Ricardo Blanco²¹, Miguel Ángel González-Gay²² and Raquel Lopez Mejias²³, ¹Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Ilerna, Madrid, Spain, ³Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁴Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, ⁵Medicine Department, Universidad de Granada, Granada, Spain, ⁶Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Rheumatology Department, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁸Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁹Division of Dermatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁰Division of Rheumatology, Hospital Universitario Lucus Augusti, Lugo, Spain, ¹¹Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹²Division of Rheumatology, Hospital Universitario Severo Ochoa, Madrid, Spain, ¹³Dermatology Department, Hospital Universitario de La Princesa, Madrid, ¹⁴Dermatology Department, Hospital Universitario de La Princesa, Madrid, Spain, ¹⁵Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹⁶Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ¹⁷Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, ¹⁸Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain, ¹⁹Basurto University Hospital, Bilbao, Spain, ²⁰Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain, ²¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²²Department of Medicine and Psychiatry, Universidad de Cantabria; Rheumatology Division, Hospital Universitario Marqués de Valdecilla; Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic diseases of the musculoskeletal system, IDIVAL, Santander, Spain. Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa, ²³IDIVAL, Santander, Spain
Background/Purpose: CD40 is a membrane glycoprotein expressed on B cells surface that activates antigen presenting cells [1]. BLK and BANK1 are components of B cells…
Abstract Number: 1566 • ACR Convergence 2022
Outcome of Vascular Involvement of Behçet Syndrome Treated with Infliximab: A Retrospective Cohort Study
gulen Hatemi¹, Nur Beyza Tukek², Sinem Nihal Esatoglu¹, Yesim Ozguler³, Sitki Safa Taflan², Melike Melikoglu¹, Serdal Ugurlu⁴, Izzet Fresko¹, Zekayi Kutlubay⁵, Sebahattin Yurdakul¹, Hasan Yazici⁶ and Vedat Hamuryudan⁷, ¹Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, ⁴Istanbul University-Cerrahpaşa, Istanbul, Turkey, ⁵Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey, ⁶Letter to Editor Rheumatology, Istanbul, Turkey, ⁷Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Vascular involvement is an important cause of morbidity and mortality in patients with Behçet syndrome (BS). We aimed to survey the efficacy and safety…
Abstract Number: 1573 • ACR Convergence 2022
Von – Willebrand Factor, a Possible Marker for Disease Activity in Vasculitis
Jomana mazareeb¹, shiri keret¹, Abid Awisat¹, Itzhak Rosner², Michel Rozenbaum³, Lisa Kaly¹, Gleb Slobodin¹ and Doron Rimar¹, ¹Bnai Zion Medical Center, Haifa, Israel, ²Bnai Zion Medical Center/Technion, Haifa, Israel, ³Bnei Zion Medical Center, Hertzeliya, Israel
Background/Purpose: Vasculitis is an inflammation of blood vessels. While in many cases markers of inflammation as c- reactive protein (CRP) or erythrocytes sedimentation rate (ESR)…
Abstract Number: 1575 • ACR Convergence 2022
Characteristics of an Internet-Based, International Cohort of Patients with a Self-Reported Diagnosis of Urticarial Vasculitis
Jason Springer¹, Tanaz Kermani², Dianne Shaw³, Kalen Larson⁴, Cristina Burroughs⁵ and Peter Merkel⁶, ¹Vanderbilt University Medical Center, Nashville, TN, ²University of California Los Angeles, Los Angeles, CA, ³Vasculitis Foundation, Chapel Hill, NC, ⁴Vasculitis Foundation, Kansas City, MO, ⁵University of South Florida, Tampa, FL, ⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Urticarial vasculitis is a markedly rare disease, with an annual incidence of < 1 per million. Hypocomplementemia is associated with systemic features and a…
Abstract Number: 1544 • ACR Convergence 2022
Is It Possible to Evaluate Polymyalgia Rheumatica Without C-reactive Protein? Concordance and Agreement Between Different PMR Activity Scores in Polymyalgia Rheumatica
Justine D'agostino¹, Valerie Devauchelle¹, Guillermo CARVAJAL ALEGRIA², Emmanuelle Dernis³, Christophe Richez⁴, Marie Truchetet⁵, Daniel Wendling⁶, ERIC TOUSSIROT⁷, aleth Perdriger⁸, jacques-eric gottenberg⁹, Renaud FELTEN¹⁰, Bruno Fautrel¹¹, laurent chiche¹², Pascal HILLIQUIN¹³, Catherine Le Henaff¹⁴, Benjamin Dervieux¹⁵, Guillaume Direz¹⁶, Isabelle Chary-Valckenaere¹⁷, Divi CORNEC¹⁸, Dewi Guellec¹⁹, Thierry MARHADOUR²⁰, Aghiles Souki¹⁹, Emmanule Nowak¹⁹ and Alain Saraux²¹, ¹Université de Bretagne Occidentale, Brest, France, ²CHRU de Tours, Tours, France, ³LE MANS general hospital, LE MANS, France, ⁴Université de Bordeaux, Bordeaux, France, ⁵Bordeaux University Hospital, Bordeaux, France, ⁶CHU, University Teaching Hospital, Besançon, France, ⁷CHU de Besançon, Besançon, France, ⁸Rennes University, Rennes, France, ⁹Strasbourg University Hospital, Strasbourg, France, ¹⁰Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ¹¹Pitié Salpêtrière Hospital, Paris, France, ¹²hopital europeen, Marseille, France, ¹³Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France, ¹⁴Morlaix Hospital, Morlaix, France, ¹⁵Mulhouse Hospital, Mulhouse, France, ¹⁶Le Mans Hospital, Le Mans, France, ¹⁷Nancy University Hospital, Vandoeuvre, France, ¹⁸CHRU Brest, Brest, France, ¹⁹Brest University Hospital, Brest, France, ²⁰CHU Cavale Blanche, Brest, France, ²¹CHU Brest, Brest, France
Background/Purpose: Today, the only disease activity score developed specifically for polymylagia rheumatica is the PMR-AS. It is a composite index built as an algebraic sum…
Abstract Number: 1580 • ACR Convergence 2022
Poor Serum Urate Control Is a Driver of Excess Cardiovascular Risk in Patients with Gout
Tate Johnson¹, Lindsay Helget², Harlan Sayles², Punyasha Roul³, James O'Dell², Ted Mikuls⁴ and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³UNMC, Omaha, NE, ⁴Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Gout patients suffer from an increased burden of cardiovascular disease (CVD). It remains unclear whether this risk is related to an excess of CVD…
Abstract Number: 1577 • ACR Convergence 2022
Impact of Cutaneous Vasculitis on Health-Related Quality-of-Life
Sarah Mann¹, Aamir Hussain², Anisha Dua³, Angelina Patrone⁴, Kalen Larson⁵, Peter Merkel⁶ and Robert Micheletti⁷, ¹Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, ²Department of Dermatology, Georgetown University, Washington, DC, ³Northwestern University, Chicago, IL, ⁴Patient Partner, Philadelphia, PA, ⁵Vasculitis Foundation, Kansas City, MO, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Departments of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cutaneous manifestations of vasculitis can cause pruritus, pain, and ulceration, and their psychosocial impacts may be significant. However, the quality-of-life (QoL) impact of skin…
Abstract Number: 1581 • ACR Convergence 2022
Presence of Sonographic Crystal Deposits and Power-Doppler Signal in Patients with Gout Fulfilling Remission Criteria: A Multicenter Study
Nalia Domínguez-Lirón¹, Eugenio De Miguel², Agustín Martínez-Sanchis³, Diana Peiteado², Blanca Garcia-Magallon⁴, Esther Vicente-Rabaneda⁵, Enrique Calvo⁶, Basilio Rodríguez⁷, Alejandro Prada⁸, Boris Anthony Blanco Cáceres⁹, José Antonio Bernal¹⁰, Francisca Sivera¹¹, Santos Castañeda⁵, Sonia Mínguez⁷, Laura Barrio⁸, Mónica Vázquez-Díaz⁹, José Miguel Senabre¹², Cristina Bohorquez¹³ and Mariano Andrès³, ¹Miguel Hernández University, Alicante, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Dr Balmis Alicante General University Hospital-ISABIAL, Alicante, Spain, ⁴Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ⁵Division of Rheumatology, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁶Hospital Universitario Infanta Leonor, Madrid, Spain, ⁷Althaia Xarxa Assistencial Universitaria De Manresa, Manresa, Spain, ⁸Hospital Universitario de Torrejon, Madrid, Spain, ⁹Hospital Universitario Ramón y Cajal, Madrid, Spain, ¹⁰Hospital Marina Baixa (Villajoyosa), Alicante, Spain, ¹¹Hospital Universitario de Elda, San Vicente del Raspeig, Spain, ¹²Hospital Marina Baixa, Villajoyosa, Spain, ¹³University Hospital Príncipe de Asturias, Immune System Diseases-Rheumatology Service, Alcalá de Henares, Madrid, Spain
Background/Purpose: The applicability of the preliminary remission criteria for gout [PMID 26414176] in clinical practice is unknown. This study evaluates the sonographic prevalence of monosodium…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].